Xencor (XNCR)
(Delayed Data from NSDQ)
$21.13 USD
+0.10 (0.48%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $21.16 +0.03 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.13 USD
+0.10 (0.48%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $21.16 +0.03 (0.14%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Zacks News
Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues
by Zacks Equity Research
Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.
Zacks.com featured highlights Xencor, Encore Wire and Silvergate Capital
by Zacks Equity Research
Xencor, Encore Wire and Silvergate Capital have been highlighted in this Screen of The Week article.
Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.
United Therapeutics (UTHR) Q1 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics' (UTHR) first-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.
JAZZ Q1 Earnings Miss, Sales Robust, 2022 Guidance Raised
by Zacks Equity Research
JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.
Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.
3 Best Profitable Stocks to Buy Using Net Income Ratio
by Tirthankar Chakraborty
Xencor (XNCR), Encore Wire (WIRE) & Silvergate Capital (SI) have been selected as the top profitable picks with a high net income ratio.
Esperion (ESPR) Q1 Earnings Beat on Robust Demand for Drugs
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports solid first-quarter results, beating estimates for earnings and sales. Cost-savings programs boost margins. Stock rallies.
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 0.96% and 66.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 157.45% and 42.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) Q4 results are expected to gain from high sales and visits volume.
Xencor (XNCR) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 8.00% and 11.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Arena (ARNA) Q3 Loss Wider Than Anticipated, Revenues Nil
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses Q3 bottom-line estimates. The company progresses with pipeline development.
Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.
Ironwood (IRWD) Q3 Earnings Top, Sales Hurt by Lower Price
by Zacks Equity Research
Ironwood (IRWD) witnesses flat year-over-year sales as growth in demand for Linzess gets partially offset by lower net price of the drug. The company maintains revenue guidance. Stock down.
United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up
by Zacks Equity Research
United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.
Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.
Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.
Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates
by Zacks Equity Research
Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates
Can Xencor (XNCR) Climb 48% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 48.1% upside potential for Xencor (XNCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
4 Small Drug Stocks That Hold Promise Despite Industry Challenges
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.